Filing Details

Accession Number:
0000899243-19-028975
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-11 19:38:35
Reporting Period:
2019-12-09
Accepted Time:
2019-12-11 19:38:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1682852 Moderna Inc. MRNA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1222012 Noubar Afeyan 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
Yes No Yes No
1255927 Jr M Edwin Kania 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No Yes No
1503559 Flagship Ventures Fund Iv, L.p. 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No Yes No
1508051 Flagship Ventures Fund Iv General Partner Llc C/O Flagship Pioneering, Inc.
55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
Yes No Yes No
1590973 Flagship Ventures Fund Iv-Rx, L.p. 55 Cambridge Parkway, Suite 800E
Cambridge MA 02142
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-12-09 6,292,342 $0.00 31,582,082 No 4 J Indirect See Footnote
Common Stock Disposition 2019-12-09 1,207,658 $0.00 8,260,938 No 4 J Indirect See Footnote
Common Stock Disposition 2019-12-09 1,735,720 $0.00 0 No 4 J Indirect See Footnote
Common Stock Disposition 2019-12-09 144,423 $18.99 31,437,659 No 4 S Indirect See Footnote
Common Stock Disposition 2019-12-09 27,714 $18.99 8,233,224 No 4 S Indirect See Footnote
Common Stock Disposition 2019-12-10 21,325 $18.96 31,416,334 No 4 S Indirect See Footnote
Common Stock Disposition 2019-12-10 4,092 $18.96 8,229,132 No 4 S Indirect See Footnote
Common Stock Disposition 2019-12-11 199,935 $18.65 31,216,399 No 4 S Indirect See Footnote
Common Stock Disposition 2019-12-11 38,366 $18.65 8,190,766 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Indirect See Footnote
No 4 J Indirect See Footnote
No 4 J Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 11,460,435 Indirect See Footnote
Common Stock 3,924 Indirect See Footnote
Common Stock 598,847 Indirect See Footnote
Footnotes
  1. On December 9, 2019, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 6,292,342 shares and 1,207,658 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,494,155 shares and 241,565 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr., each a manager of Flagship Fund IV GP, each received 598,847 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
  2. Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Flagship Pioneering, Inc. ("Pioneering"), he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  3. Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. While Mr. Kania is retired from Pioneering he continues to serve as a manager of the Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  4. Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Pioneering, he continues to serve as a manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.90 to $19.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.95 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.65 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  8. Shares held by Flagship VentureLabs IV LLC ("VentureLabs IV"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship Fund IV GP. While Mr. Kania is retired from Pioneering he continues to serve as a manager of the Flagship Fund IV GP. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  9. Shares held by Pioneering. Noubar B. Afeyan, Ph.D. is the CEO and sole stockholder of Pioneering. Each of the reporting persons except for Pioneering disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
  10. Shares held by Noubar B. Afeyan, Ph.D. Each of the reporting persons except for Noubar B. Afeyan, Ph.D. disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.